93 results on '"Rosso C."'
Search Results
2. A nutrigenetic precision approach for the management of NAFLD
3. Low adherence to Mediterranean Diet is associated to sCD163 levels in patients with MAFLD
4. The use of AGILE 3+ and AGILE 4 for the prediction of advanced fibrosis and cirrhosis in patients with Non-Alcoholic Fatty Liver Disease
5. T.07.3 PROGNOSTIC VALUE OF LIVER STIFFNESS AND FIB-4 SCORE IN INDIVIDUALS WITH CIRRHOSIS DUE TO NON-ALCOHOLIC FATTY LIVER DISEASE WITHOUT PREVIOUS LIVER DECOMPENSATION
6. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes a pro-tumorigenic inflammatory response
7. Interferon gamma-induced protein 10 levels are associated with insulin resistant components in subjects with non-alcoholic fatty liver disease
8. Social jetlag and mediterranean diet adherence are associated to liver fibrosis in patients with non-alcoholic fatty liver disease
9. Echocardiography-based markers of subclinical cardiac dysfunction in individuals with Non-Alcoholic Fatty Liver Disease and preserved ejection fraction: Interim data from a prospective study
10. Prognostic value of simple non-invasive tests for the risk stratification of hcc development in patients with cirrhosis due to non-alcoholic fatty liver disease
11. Irisin alleviates liver oxidative stress in non-obese, non-diabetic individuals with Non-Alcoholic Fatty Liver Disease
12. Steroidomic profiles across the spectrum of liver damage in non-alcoholic fatty liver disease
13. The role of histidine-rich glycoprotein in non alcoholic steatohepatitis-related experimental liver carcinogenesis
14. MiRNome profiling of circulating extracellular vesicles in patients with chronic hepatitis delta treated with pegylated interferon alpha
15. Liver cancer-specific isoform of serine protease inhibitor Kazal for the detection of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease
16. The OSM/OSMRβ signalling axis in the development of MASLD-related hepatocellular carcinoma
17. Response to a 6-month personalized dietary intervention in patients with metabolic dysfunction-associated steatotic liver disease
18. Significant decrease of hepatic steatosis is associated with decreased PAI-I levels in overweight/obese subjects with Metabolic-dysfunction Associated Steatotic Liver Disease
19. The glucokinase regulator gene (GCKR) rs780094 C>T single nucleotide polymorphism affect diet response in overweight/obese subjects with metabolic-dysfunction associated steatotic liver disease
20. Chrononutrition as a dietary strategy to reduce hepatic steatotis in patients with metabolic dysfunction-associated steatotic liver disease
21. Hepatocellular carcinoma incidence and risk stratification in patients with metabolic dysfunction-associated steatotic liver disease on long-term follow-up
22. OC-07A machine learning approach for the classification of NASH vs NAFL in diabetic and non-diabetic subjects reveals a strong association between liver inflammation and adipose tissue dysfunction
23. Increased serum ferritin levels predict long-term mortality in patients with NAFLD
24. Oncostatin M, a novel profibrogenic mediator, is involved in the progression non-alcoholic fatty liver disease and stimulates migration of myofibroblasts
25. Risk of developing hepatocellular carcinoma (HCC) in patients with cirrhosis of viral etiology evaluated by the association of alpha-fetoprotein (AFP), protein induced by vitamin K absence or antagonist-II (PIVKA-II) and glypican-3 (GPC-3)
26. Interplay between metabolic derangement, hepatic fibrogenesis and macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
27. Metabolomic profile of morbidly obese NAFLD: effect of weight loss by exenatide or diet
28. NASH-related liver carcinogenesis is critically affected by hypoxia-inducible factor 2α
29. Selenoprotein P levels discriminate the degree of hepatic steatosis and are related to the NAS score in patients with non-alcoholic fatty liver disease
30. Prevalence of patients with non-alcoholic fatty liver disease: from primary care to tertiary centers. The Turin experience
31. Longitudinal prognostic value of the most common algorithms for fibrosis in non-alcoholic fatty liver disease. An international study in non-cirrhotic, biopsy-proven patients
32. P116 Eosinophilic colitis: a case report (not everything is Celiac disease, not everything is IBD)
33. Bile acid composition modulates insulin resistance in non-diabetic patients with NAFLD
34. Increased hepatic glucose production and insulin resistance are associated to increased plasma concentrations of glucogenic amino acids in subjects with NAFLD
35. Hepatocellular carcinoma and metabolic risk factors in a main reference center in Italy
36. Absolute quantification of intrahepatic HBV covalently-closed-circular DNA by droplet digital PCR
37. Adipose tissue insulin resistance is associated with macrophage activation in non-diabetic patients with non-alcoholic fatty liver disease
38. Angiopoietin-like4 is associated with lipid metabolism and severe fibrosis in non-diabetic patients with non-alcoholic fatty liver disease
39. Hepatitis B core-related antigen levels during nucleos(t)ide analogues or pegylated-interferon treatment in patients chronically infected with HBV genotype-D
40. Metabolic Syndrome after liver transplantation: have risk factors changed over time?
41. Insulin resistance and liver damage are associated with early signs of left ventricular systolic dysfunction in non-diabetic, non-dyslipidemic, normotensive patients with Nonalcoholic fatty Liver Disease
42. PNPLA3 RS738409 I748M is associated with steatohepatitis in non obese subjects with hepatitis C
43. Liver damage can be associated with deregulation of the de novo lipogenesis pathway in subjects with Non Alcoholic Fatty Liver Disease
44. Alteration in glucose metabolism after an oral glucose load in patients with non-alcoholic fatty liver disease
45. Alteration in lipid metabolism after an oral fat load in non-alcoholic fatty liver disease
46. Effects of glucose and fat load on oxidative stress in patients with non-alcoholic fatty liver disease
47. MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver
48. F-22 Metabolic alterations of lipid kinetics in NAFLD patients and their contribution to liver damage
49. OC-09 Contribution of visceral fat and hepatic fat to metabolic derangements and liver damage in NAFLD patients
50. F-1 IL28B gene variants and metabolic profile in patients with genotype 1 chronic hepatitis C
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.